Loading…

Impact of pharmacogenetics on aspirin resistance: a systematic review

Abstract Background  Pharmacogenetics promises better control of diseases such as cardiovascular disease (CVD). Acetylsalicylic acid, aspirin, prevents the formation of an activating agent of platelet aggregation and vasoconstriction, and it is used to prevent CVD. Nevertheless, patients may have tr...

Full description

Saved in:
Bibliographic Details
Published in:Arquivos de neuro-psiquiatria 2023-01, Vol.81 (1), p.062-073
Main Authors: Silva, Gustavo Figueiredo da, Lopes, Bruno Mattei, Moser, Vinicius, Ferreira, Leslie Ecker
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background  Pharmacogenetics promises better control of diseases such as cardiovascular disease (CVD). Acetylsalicylic acid, aspirin, prevents the formation of an activating agent of platelet aggregation and vasoconstriction, and it is used to prevent CVD. Nevertheless, patients may have treatment failure due to genetic variants that modify the metabolism of the drug causing aspirin resistance (AR). Objectives  To realize a systematic literature review to determine the impact of genetic variants on AR. Methods  Articles published in the MEDLINE/PubMed, Cochrane, Scopus, LILACS, and SCIELO databases were systematically screened. A total of 290 articles were identified and 269 articles were excluded because they did not comply with the previously established inclusion criteria. A total of 20 case-control studies and 1 cohort was included. Results  The genetic variants rs1126643 ( ITGA2 ), rs3842787 ( PTGS1 ), rs20417 ( PTGS2 ), and rs5918 ( ITGB3 ) were the most studied. As for relevance, of the 64 genetic variants evaluated by the articles, 14 had statistical significance ( p  
ISSN:0004-282X
1678-4227
1678-4227
DOI:10.1055/s-0042-1758445